Detalhe da pesquisa
1.
A Phase Ib/II study of IGF-neutralising antibody xentuzumab with enzalutamide in metastatic castration-resistant prostate cancer.
Br J Cancer
; 129(6): 965-973, 2023 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37537253
2.
Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1-2 trial.
Lancet Oncol
; 20(3): 383-393, 2019 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-30745090
3.
Safety and tolerability of long-term treatment with darolutamide in patients with metastatic castration-resistant prostate cancer.
Prostate Cancer Prostatic Dis
; 2023 Oct 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-37884613
4.
ODM-204, a Novel Dual Inhibitor of CYP17A1 and Androgen Receptor: Early Results from Phase I Dose Escalation in Men with Castration-resistant Prostate Cancer.
Eur Urol Focus
; 6(1): 63-70, 2020 01 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-30194031